Dr. Wendye Robbins, M.D., serves as Chief Executive Officer, President and Director at Blade Therapeutics, Inc. Dr. Robbins co-founded early biopharmaceutical companies NeurogesX, Inc. (NASD: NGSX, sold to Acorda Therapeutics), Limerick BioPharma, Labrys Biologics (sold to TEVA 2014), Decibel Therapeutics (Third Rock Ventures), and Blade Therapeutics. She served as Chief Executive Officer, President and Director at Limerick BioPharma, Inc. Dr. Robbins serves as Member of Scientific and Medical Advisory Board at Cerimon Pharmaceuticals, Inc. Dr. Robbins serves as Director at Theraclone Sciences, Inc. She has functioned as an outside advisor to investors and in this capacity served as development advisor to Rinat Neurosciences, supporting the 2006 Pfizer acquisition. She also managed diligence and development planning to enable spinout of a former Rinat / Pfizer biologic asset into Labrys Biologics. She has been a scientific and strategic advisor to many entrepreneurs, nascent biotechs and pharmaceutical companies. Her expertise includes small and large molecule development from discovery through translational research through the clinic. She served as Assistant Professor of Anesthesiology at UCSF from 1995 to 2000 and has been teaching faculty at the Stanford University School of Medicine since 2002. She is board certified in anesthesiology. Dr. Robbins received her BS from the University of California, Berkeley Haas School of Business and her MD from the Medical College of Pennsylvania in 1990. She completed post graduate training in internal medicine at the Hospital of the University of Pennsylvania from 1990 to 1991 and in anesthesiology and pain medicine at the Johns Hopkins University Medical Institutions from 1991 to 1995. Dr. Wendye Robbins, M.D., serves as Chief Executive Officer, President and Director at Blade Therapeutics, Inc. Dr. Robbins co-founded early biopharmaceutical companies NeurogesX, Inc. (NASD: NGSX, sold to Acorda Therapeutics), Limerick BioPharma, Labrys Biologics (sold to TEVA 2014), Decibel Therapeutics (Third Rock Ventures), and Blade Therapeutics. She served as Chief Executive Officer, President and Director at Limerick BioPharma, Inc. Dr. Robbins serves as Member of Scientific and Medical Advisory Board at Cerimon Pharmaceuticals, Inc. Dr. Robbins serves as Director at Theraclone Sciences, Inc. She has functioned as an outside advisor to investors and in this capacity served as development advisor to Rinat Neurosciences, supporting the 2006 Pfizer acquisition. She also managed diligence and development planning to enable spinout of a former Rinat / Pfizer biologic asset into Labrys Biologics. She has been a scientific and strategic advisor to many entrepreneurs, nascent biotechs and pharmaceutical companies. Her expertise includes small and large molecule development from discovery through translational research through the clinic. She served as Assistant Professor of Anesthesiology at UCSF from 1995 to 2000 and has been teaching faculty at the Stanford University School of Medicine since 2002. She is board certified in anesthesiology. Dr. Robbins received her BS from the University of California, Berkeley Haas School of Business and her MD from the Medical College of Pennsylvania in 1990. She completed post graduate training in internal medicine at the Hospital of the University of Pennsylvania from 1990 to 1991 and in anesthesiology and pain medicine at the Johns Hopkins University Medical Institutions from 1991 to 1995.

 Medical & Surgical Pathology